George J Taylor1,2, Dorothy M Lee2, Catalin F Baicu1,2, Michael R Zile1,2. 1. 1 Department of Medicine, Medical University of South Carolina , Charleston, South Carolina. 2. 2 Ralph H. Johnson Department of Veterans Affairs Medical Center , Charleston, South Carolina.
Abstract
BACKGROUND: Palliative care for advanced heart failure (HF) is generally recommended. However, few reports have focused on the particulars of treatment, or the clinical course of HF on a specific treatment regimen. OBJECTIVE: Palliation adequate to allow patients to avoid HF admission and die at home. METHODS: Patients from a veterans administration regional practice with multiple, recent hospital admissions were enrolled in community hospice programs. Treatment of HF with reduced left ventricular ejection fraction (HFrEF) included guidelines-directed medical therapy, digoxin, opioids, and oral bumetanide (with metolazone as needed) rather than intravenous diuretics. Levodopa (l-dopa) was added when conventional therapy failed to control symptoms. HF with preserved EF was also treated with bumetanide and opioids. RESULTS: Thirty male veterans, 23 of them with HFrEF, had 90 HF admissions in the 6 months before enrollment, and 3 HF admissions during follow-up of at least 14 months. Twenty-one patients died, 18 of them at home; 14 died within 5 months, and the rest lived much longer. Failure to improve with initial therapy predicted early death. Results were similar for those with reduced and preserved left ventricular ejection fraction. L-dopa was started in 13 patients and tolerated by 8 patients; functional class improved and B-type natriuretic peptide declined after treatment. CONCLUSIONS: With this treatment protocol, there were few HF admissions and patients were able to die at home. It can be used as a guide to therapy, or as an approach that can be tested with additional study.
BACKGROUND: Palliative care for advanced heart failure (HF) is generally recommended. However, few reports have focused on the particulars of treatment, or the clinical course of HF on a specific treatment regimen. OBJECTIVE: Palliation adequate to allow patients to avoid HF admission and die at home. METHODS:Patients from a veterans administration regional practice with multiple, recent hospital admissions were enrolled in community hospice programs. Treatment of HF with reduced left ventricular ejection fraction (HFrEF) included guidelines-directed medical therapy, digoxin, opioids, and oral bumetanide (with metolazone as needed) rather than intravenous diuretics. Levodopa (l-dopa) was added when conventional therapy failed to control symptoms. HF with preserved EF was also treated with bumetanide and opioids. RESULTS: Thirty male veterans, 23 of them with HFrEF, had 90 HF admissions in the 6 months before enrollment, and 3 HF admissions during follow-up of at least 14 months. Twenty-one patients died, 18 of them at home; 14 died within 5 months, and the rest lived much longer. Failure to improve with initial therapy predicted early death. Results were similar for those with reduced and preserved left ventricular ejection fraction. L-dopa was started in 13 patients and tolerated by 8 patients; functional class improved and B-type natriuretic peptide declined after treatment. CONCLUSIONS: With this treatment protocol, there were few HF admissions and patients were able to die at home. It can be used as a guide to therapy, or as an approach that can be tested with additional study.
Authors: Eiran Z Gorodeski; Eric C Chu; Jennifer R Reese; Mehdi H Shishehbor; Eileen Hsich; Randall C Starling Journal: Circ Heart Fail Date: 2009-05-14 Impact factor: 8.790
Authors: Andrew P Ambrosy; Javed Butler; Ali Ahmed; Muthiah Vaduganathan; Dirk J van Veldhuisen; Wilson S Colucci; Mihai Gheorghiade Journal: J Am Coll Cardiol Date: 2014-03-05 Impact factor: 24.094
Authors: Robert C Bourge; Jerome L Fleg; Gregg C Fonarow; John G F Cleland; John J V McMurray; Dirk J van Veldhuisen; Mihai Gheorghiade; Kanan Patel; Inmaculada B Aban; Richard M Allman; Connie White-Williams; Michel White; Gerasimos S Filippatos; Stefan D Anker; Ali Ahmed Journal: Am J Med Date: 2013-03-12 Impact factor: 4.965